Pfizer

On its Q2 2026 earnings call Pfizer said AI is already lowering manufacturing costs and improving yields.

Pfizer scientists published a generative AI workflow that drafts pharmacokinetic sections of clinical study reports and scored its output against manually written reports.

Pfizer and Boltz agreed to tune Boltz's open biomolecular foundation models on Pfizer's historical data into exclusive models and roll them out to Pfizer scientists for small-molecule and biologics design.

Partners: Boltz

PostEra extended its machine-learning drug discovery alliance with Pfizer, adding more small-molecule targets and a new antibody-drug conjugate payload track, for a total potential value of about $610 million.

Partners: PostEra

Microsoft reports that Pfizer has built and deployed more than 300 Copilot Studio agents across the company.

Partners: Microsoft

Pfizer stood up Vox, its own internally approved generative AI platform on AWS, and described it in a re:Invent keynote as the base for many use cases.

Partners: AWS

Pfizer built Charlie, a generative AI platform for creating marketing content that also assists fact-checking and legal review, and was rolling it out to marketing and agency partners.

Partners: Publicis Groupe, IPG

Pfizer extended its agreement with Saama to scale an AI-driven clinical data quality tool across its wider global study portfolio.

Partners: Saama